Compare Micron Technology, Inc. (MU) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Micron Technology, Inc. trades at $1,027.71 (market cap $1.17T), while Royalty Pharma plc Class A Ordinary Shares trades at $56.95 (market cap $25.27B). The key difference: Micron Technology, Inc. is far larger — about 46.3× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays the higher dividend (1.66%). Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 48 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| MU | RPRX | |
|---|---|---|
Market Cap | $1.17T | $25.27B |
Volume | 29,425,906 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $1.21K | $63.96 |
52-Week Low | $181.60 | $35.44 |
Typical Hold Time | 48 Days | 1 Days |
Enterprise Value | $1.13T | $32.50B |
Dividend Yield | 0.06% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,026.85, down 5.62% over 24 hours, despite strong fundamental performance. The stock shows bullish technical signals with support at $1,020 and resistance at $1,064. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $33.42 surpassing the $31.77 estimate. Revenue surged to $37.38 billion in 2025 with net income of $8.54 billion, while analyst consensus remains strongly bullish with 82.85% buy ratings and a $1,590 price target.
Outlook remains positive driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030. Key risks include cyclical memory pricing and potential growth deceleration. The valuation at P/E 13.94 appears reasonable given robust profitability margins and projected 2026 revenue of $133.2 billion. Institutional sentiment supports further upside if execution continues.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
